Shindiapina, P., & Alinari, L. (2018). Pembrolizumab and its role in relapsed/refractory classical Hodgkin’s lymphoma: Evidence to date and clinical utility. Ther Adv Hematol.
Styl cytowania ChicagoShindiapina, Polina, i Lapo Alinari. "Pembrolizumab and Its Role in Relapsed/refractory Classical Hodgkin’s Lymphoma: Evidence to Date and Clinical Utility." Ther Adv Hematol 2018.
Styl cytowania MLAShindiapina, Polina, i Lapo Alinari. "Pembrolizumab and Its Role in Relapsed/refractory Classical Hodgkin’s Lymphoma: Evidence to Date and Clinical Utility." Ther Adv Hematol 2018.
Uwaga: Te cytaty mogą odróżniać się od wytycznej twojego fakultetu..